5.45
0.30 (5.83%)
| Previous Close | 5.15 |
| Open | 5.25 |
| Volume | 1,332,442 |
| Avg. Volume (3M) | 1,366,406 |
| Market Cap | 753,397,056 |
| Price / Sales | 48.78 |
| Price / Book | 0.680 |
| 52 Weeks Range | |
| Earnings Date | 30 Jul 2025 - 4 Aug 2025 |
| Operating Margin (TTM) | -4,568.83% |
| Diluted EPS (TTM) | -4.23 |
| Quarterly Revenue Growth (YOY) | -94.60% |
| Total Debt/Equity (MRQ) | 9.21% |
| Current Ratio (MRQ) | 6.79 |
| Operating Cash Flow (TTM) | -415.08 M |
| Levered Free Cash Flow (TTM) | -310.09 M |
| Return on Assets (TTM) | -23.52% |
| Return on Equity (TTM) | -44.59% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Vir Biotechnology, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -1.5 |
| Price Volatility | 0.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 0.5 |
| Average | 0.30 |
|
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 10.62% |
| % Held by Institutions | 79.11% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Gates Foundation | 30 Sep 2024 | 1,559,142 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 21.00 (Goldman Sachs, 285.32%) | Buy |
| Median | 17.50 (221.10%) | |
| Low | 14.00 (Needham, 156.88%) | Buy |
| Average | 17.50 (221.10%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 5.06 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 22 May 2025 | 14.00 (156.88%) | Buy | 4.61 |
| 12 May 2025 | 14.00 (156.88%) | Buy | 5.30 | |
| Goldman Sachs | 17 Apr 2025 | 21.00 (285.32%) | Buy | 5.50 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 28 May 2025 | Announcement | Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 |
| 20 May 2025 | Announcement | Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit |
| 12 May 2025 | Announcement | Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference |
| 09 May 2025 | Announcement | Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study |
| 07 May 2025 | Announcement | Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results |
| 30 Apr 2025 | Announcement | Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025 |
| 24 Apr 2025 | Announcement | Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |